Investors Sell Abbott Laboratories (ABT) on Strength (ABT)

Investors sold shares of Abbott Laboratories (NYSE:ABT) on strength during trading on Monday. $53.23 million flowed into the stock on the tick-up and $91.24 million flowed out of the stock on the tick-down, for a money net flow of $38.01 million out of the stock. Of all equities tracked, Abbott Laboratories had the 20th highest net out-flow for the day. Abbott Laboratories traded up $0.21 for the day and closed at $73.54

Several research analysts have commented on ABT shares. Morgan Stanley boosted their target price on Abbott Laboratories from $82.00 to $85.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 2nd. Citigroup downgraded Abbott Laboratories from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $72.00 to $68.00 in a research note on Wednesday, January 2nd. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $80.00 target price for the company in a research note on Monday, January 28th. Barclays started coverage on Abbott Laboratories in a research note on Monday, October 15th. They set an “overweight” rating and a $80.00 target price for the company. Finally, Goldman Sachs Group raised Abbott Laboratories from a “neutral” rating to a “buy” rating and set a $74.10 target price for the company in a research note on Sunday, December 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $79.48.

The company has a debt-to-equity ratio of 0.62, a current ratio of 1.42 and a quick ratio of 1.13. The company has a market cap of $128.79 billion, a PE ratio of 25.53, a P/E/G ratio of 1.95 and a beta of 1.14.



Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, January 23rd. The healthcare product maker reported $0.81 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.81. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.82 billion. Abbott Laboratories had a net margin of 7.74% and a return on equity of 16.50%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.74 EPS. On average, equities research analysts predict that Abbott Laboratories will post 3.2 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 15th. Shareholders of record on Tuesday, January 15th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 1.74%. The ex-dividend date of this dividend is Monday, January 14th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.28. Abbott Laboratories’s dividend payout ratio is currently 44.44%.

In other news, Director John G. Stratton bought 3,455 shares of the firm’s stock in a transaction on Thursday, January 31st. The stock was acquired at an average price of $72.32 per share, with a total value of $249,865.60. Following the transaction, the director now owns 3,558 shares of the company’s stock, valued at approximately $257,314.56. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jaime Contreras sold 177,457 shares of the stock in a transaction that occurred on Wednesday, January 30th. The shares were sold at an average price of $70.00, for a total transaction of $12,421,990.00. Following the sale, the insider now directly owns 100,985 shares of the company’s stock, valued at approximately $7,068,950. The disclosure for this sale can be found here. Corporate insiders own 0.74% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in ABT. Schroder Investment Management Group boosted its holdings in shares of Abbott Laboratories by 73.3% during the 2nd quarter. Schroder Investment Management Group now owns 133,744 shares of the healthcare product maker’s stock worth $8,194,000 after buying an additional 56,582 shares in the last quarter. We Are One Seven LLC bought a new position in shares of Abbott Laboratories during the 3rd quarter worth approximately $225,000. Personal Capital Advisors Corp bought a new position in shares of Abbott Laboratories during the 3rd quarter worth approximately $201,000. Berkshire Asset Management LLC PA boosted its holdings in shares of Abbott Laboratories by 4.4% during the 3rd quarter. Berkshire Asset Management LLC PA now owns 288,197 shares of the healthcare product maker’s stock worth $21,142,000 after buying an additional 12,102 shares in the last quarter. Finally, Community Bank & Trust Waco Texas boosted its holdings in shares of Abbott Laboratories by 2.8% during the 3rd quarter. Community Bank & Trust Waco Texas now owns 38,583 shares of the healthcare product maker’s stock worth $2,830,000 after buying an additional 1,061 shares in the last quarter. 74.36% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece of content was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://dakotafinancialnews.com/2019/02/12/investors-sell-abbott-laboratories-abt-on-strength-abt.html.

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Further Reading: Are Wall Street analysts’ stock ratings worth following?

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply